You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2022

ID: PET 2022-1 Jan 2023
Type of Content: Guidelines & Advice, Evidence Summary
Document Status: Current
R. Poon and the Program in Evidence-Based Care Disease Site Group Reviewers

Guideline Objective:

As part of a regular monitoring program recommended by the PEBC, a systematic review of recent evidence on the use of PET in patients with cancer, sarcoidosis, epilepsy or dementia is conducted every six months. This report is intended to be a high-level, brief summary of the identified evidence, and not a detailed evaluation of its quality and relevance.

Patient Population:

Adult and pediatric patients with suspected or diagnosed cancer(s), sarcoidosis, epilepsy or dementia (The cancer is not limited to those cancers with approved or Ontario Health Insurance (OHIP) insured services).

Intended Guideline Users:

Ontario PET Steering Committee

Research Questions:

What is the role of positron emission tomography (PET) in the clinical management of patients with cancer, sarcoidosis, epilepsy or dementia with respect to:

  • Diagnosis and staging
  • Assessment of treatment response
  • Detection and restaging of recurrence and Evaluation of metastasis
  • Outcomes of interest are: survival, quality of life, prognostic indicators, time until recurrence, safety outcomes (e.g., avoidance of unnecessary surgery), and change in clinical management.